Mr. Heffernan is Founder, President and CEO of Collegium Pharmaceutical, Inc. Prior to this, Mr. Heffernan was Founder, President, & CEO of Onset Therapeutics Inc. Before this, Mr. Heffernan had held positions as Co-Founder, President, & CEO of Clinical Studies Ltd, and as President & CEO of PhyMatrix Inc.
Mr. Heffernan has a BS degree in Pharmacy from the University of Connecticut and is a registered pharmacist.
Mr. Heffernan is an independent board member.
Chair of the Nominating and Governance Committee & Member of the Remuneration Committee
Ms. Agger has been a Board Member of Veloxis since April 2010. Ms. Agger is Managing Partner of Lundbeckfond Ventures, a company fully owned by the Lundbeck Foundation. She joined the company on September 1, 2009. Prior to this, Ms. Agger was CEO of 7TM Pharma A/S, which she cofounded in late 2000, and from 1996 to 2000 she was part of the management team at NeuroSearch A/S, responsible for business development and licensing.
Ms. Agger has a Master of Science in Biology from Copenhagen University and an MBA from the Henley Business School, UK.
Ms. Agger is a board member of Klifo A/S, PsiOxus Therapeutics Ltd, Cydan LLC, scPharmaceuticals LLC, Thesan Pharamceuticals Inc, and Vtesse Pharma.
Ms. Agger is an independent board member.
Member of the Audit Committee & Member of the Remuneration Committee
Mr. Götzsche has been a Board Member of Veloxis since April 2008. Mr. Götzsche is Executive Vice President and Chief Financial Officer at H. Lundbeck. He joined Lundbeck on September 1, 2007.After finishing his education in 1991, he joined PricewaterhouseCoopers in Denmark. From 1998 through 2001, Mr. Götzsche was Sales Manager with the SAS Institute Inc. He became Director of Group Accounting and Reporting for Group 4 Falck A/S. Before joining Lundbeck, Mr. Götzsche held the post of Chief Financial Officer for the Berlingske Officin A/S from 2005.
Mr. Götzsche holds an MS degree in Accounting from the University of Southern Denmark and became a state-authorized public accountant in 1997.
Mr. Götzsche is a board member and chair of the Audit Committee of DFDS A/S.
Mr. Götzsche is Chairman of the Board of Rosborg Møbler A/S.
Mr. Götzsche is an independent board member.
Chair of the Audit Committee
Dr. Viksmoen has been a Board Member of Veloxis since July 2016. Dr. Viksmoen has over 20 years of experience in international pharmaceuticals. Most recently, Dr. Viksmoen has served as a Special Advisor to the Board Strategy Committee of GN Store Nord A/S.
Prior to this, Dr. Viksmoen was President & CEO of GN ReSound A/S, the world's fourth largest hearing-aid manufacturer, and, from 2006 to 2010, he was the CEO of Biotec Pharmacon ASA, a Norwegian biotechnology startup.
Dr. Viksmoen received his Doctor of Medicine from the University of Oslo and spent ten years as a practicing surgeon before entering the pharmaceutical industry.
Dr. Viksmoen is an independent board member.
Member of the Nominating and Governance Committee
Dr. Wotton is President and CEO of Sigilon Inc. He was previously President and CEO of Ocata Therapeutics, Inc. (NASDAQ: OCAT) joining the company in July 2014 and managing it through a take-over by Astellas Pharma, Inc., in a US$379 million all cash transaction.
Prior to Ocata, Dr. Wotton had served as President and CEO of Antares Pharma Inc. (NASDAQ: ATRS), since October, 2008. Prior to joining Antares, Dr. Wotton was the CEO of Topigen Pharmaceuticals and prior to Topigen, he was the Global Head of Business Development of SkyePharma PLC.
Earlier in his career he held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr. Wotton is a member of the boards of Vericel Corporation (NASDAQ:VCEL) and Cynata Therapeutics (ASX:CYP) and also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada.
Mr. Radie is president, chief executive officer and a member of Egalet's board of directors and has been since March 2012. Mr. Radie has had a successful career with more than three decades in the industry and has been responsible for the sale of five companies.
In 2005, Mr. Radie led the sale of Vicuron Pharmaceuticals to Pfizer for $1.9 billion and most recently he was responsible for the sale of Topaz Pharmaceuticals Inc. to Sanofi Pasteur for an undisclosed amount. Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Prestwick Pharmaceuticals, Inc., Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and served as a director of Affinium Pharmaceuticals, Ltd. from July 2012 to March 2014, when a majority of Affinium's assets were acquired by a third party.
Mr. Radie began his career in the life sciences at Eli Lilly and Company where he worked for 18 years in sales and marketing positions with increasing levels of responsibility. Mr. Radie serves on the board of Paratek Pharmaceuticals, a biopharmaceutical company, Pennsylvania Bio, an industry group supporting Pennsylvania life sciences companies, Veloxis, a public commercial-stage company, and Horse Power for Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer.